Cronos Group (CRON) Q4 2024 earnings summary

Executive summary

• Achieved 35% year-over-year net revenue growth to $117.6 million, with Q4 net revenue up 27% to $30.3 million, driven by strong performance in Canada and Israel and growing international markets.

• Nearly doubled adjusted gross margins and improved operating cash flow by $61.7 million to positive $18.8 million.

• Maintained a robust balance sheet with $859 million in cash and cash equivalents, supporting future growth and innovation.

• Solidified market leadership in Canada and Israel, with Spinach becoming the top cannabis brand in Canada and Peace Naturals leading in Israel.

• Strategic investments and R&D breakthroughs enhanced cultivation, product innovation, and international expansion.

Financial highlights

• Q4 gross profit was $10.8 million (36% margin), up from $1.9 million (8%) in Q4 2023; adjusted gross profit was $9 million (30% margin) after purchase accounting adjustments.

• Full-year adjusted gross margin improved by 12 percentage points to 26%.

• Q4 adjusted EBITDA was -$7.2 million, a $7.6 million or 51% improvement year-over-year.

• Net income for FY 2024 was $40 million, compared to a net loss of $70.4 million in 2023.

• Free cash flow for 2024 was $5.7 million, a $51.9 million improvement from 2023.

Outlook and guidance

• Expect operating expenses to remain flat in 2025, even with GrowCo's addition.

• Anticipate continued strong market position and growth, with new supply from GrowCo expansion expected to drive further growth in the second half of 2025.

• Focused on innovation, operational excellence, and strategic expansion for 2025.

• Achieved $8.7 million in operating expense savings in 2024, meeting the $5–$10 million target.